ArticleElectrolyte & blood pressure : E & BP2026
Patient and Clinician Perspectives on Hyperkalemia Management Under Cardio-Kidney-Protective Therapy: A Three-Stakeholder Cross-Sectional Survey.
Article in Electrolyte & blood pressure : E & BP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Maintaining renin-angiotensin system inhibitor (RASi) and mineralocorticoid receptor antagonist (MRA) therapy in patients with hyperkalemia is now favored by contemporary guidelines, yet the perspectives of patients and clinicians on this shift have rarely been examined in parallel. Methods: We conducted three parallel descriptive cross-sectional surveys in Korea between April and May 2026: a patient survey distributed through a kidney-disease patient community; a nephrologist survey; and a multispecialty physician survey. Patients, nephrology specialists, and multispecialty physicians were analyzed separately and in a combined nephrologist-versus-non-nephrologist comparison. Results: A total of 125 patients, 82 nephrologists, and 255 multispecialty physicians completed the survey. Patient awareness of hyperkalemia was high (perceived risk, 3.97; 95% confidence interval, 3.84-4.10). More patients preferred potassium-lowering medication (68.8%) over strict dietary control (31.2%) for hyperkalemia management. Clinicians rated maintenance of RASi and MRA as 3.81 (3.72-3.90) and 3.47 (3.37-3.56), respectively; nephrologists rated maintenance as more important than non-nephrologists for both classes (p Conclusion: Patients preferred to maintain cardio-kidney-protective therapy. A specialty gap in this preference was observed between nephrologists and non-nephrology clinicians, indicating a need to broaden clinician awareness of the full spectrum of hyperkalemia management options, including the more active use of potassium-lowering agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.